Cue Biopharma Inc
CUE0.765USD
+0.028+3.77%
交易中 （美東）報價延遲15分鐘
47.29M總市值
虧損本益比TTM
關於 Cue Biopharma Inc 公司
Cue Biopharma, Inc. 是一家臨牀階段的生物製藥公司，正在開發一種新型治療生物製劑，以選擇性調節疾病特異性 T 細胞。該公司的平臺 Immuno-STAT（T 細胞的選擇性靶向和改變）和生物製劑旨在通過選擇性調節疾病特異性 T 細胞來發揮人體內在免疫系統的治療潛力，而不會產生廣泛的全身免疫調節的不良影響。其兩種腫瘤藥物候選產品 CUE-101 和 CUE-102 是基於白細胞介素 2 (IL-2) 的 CUE-100 系列的典型項目，代表了在美國和西歐地區流行的 HLA-A02 等位基因。CUE-101 HLA-A02 被設計用於治療人乳頭瘤病毒陽性的頭頸部鱗狀細胞癌 (HNSCC)。 CUE-102 HLA-A02，針對 Wilms 腫瘤 1 蛋白，這是一種已知在 20 多種不同癌症中過度表達的癌胚抗原。
公司簡介
公司代碼CUE
公司名稱Cue Biopharma Inc
上市日期Jan 02, 2018
CEOMr. Daniel R. (Dan) Passeri, J.D.
員工數量41
證券類型Ordinary Share
年結日Jan 02
公司地址40 Guest Street
城市BOSTON
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編02135
電話16179492680
網址https://www.cuebiopharma.com/
公司代碼CUE
上市日期Jan 02, 2018
CEOMr. Daniel R. (Dan) Passeri, J.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Daniel R. (Dan) Passeri, J.D.
Mr. Daniel R. (Dan) Passeri, J.D.
Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Director
164.58K
--
Dr. Frank Morich, M.D., Ph.D.
Dr. Frank Morich, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
28.00K
--
Mr. Patrick Verheyen
Mr. Patrick Verheyen
Independent Director
Independent Director
8.17K
--
Mr. Jill Broadfoot
Mr. Jill Broadfoot
Director
Director
--
--
Mr. Pasha Sarraf
Mr. Pasha Sarraf
Independent Director
Independent Director
--
--
Ms. Lucinda Warren
Ms. Lucinda Warren
Chief Business officer
Chief Business officer
--
--
Mr. Colin G. Sandercock, J.D.
Mr. Colin G. Sandercock, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
--
--
Dr. Peter A. Kiener, Ph.D.
Dr. Peter A. Kiener, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matteo Levisetti, M.D.
Mr. Matteo Levisetti, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Pamela Garzone, Ph.D.
Dr. Pamela Garzone, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Daniel R. (Dan) Passeri, J.D.
Mr. Daniel R. (Dan) Passeri, J.D.
Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Director
164.58K
--
Dr. Frank Morich, M.D., Ph.D.
Dr. Frank Morich, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
28.00K
--
Mr. Patrick Verheyen
Mr. Patrick Verheyen
Independent Director
Independent Director
8.17K
--
Mr. Jill Broadfoot
Mr. Jill Broadfoot
Director
Director
--
--
Mr. Pasha Sarraf
Mr. Pasha Sarraf
Independent Director
Independent Director
--
--
Ms. Lucinda Warren
Ms. Lucinda Warren
Chief Business officer
Chief Business officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月2日 週六
更新時間: 8月2日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Bleichroeder LP
6.63%
Catalytic Wealth RIA, LLC
4.42%
The Vanguard Group, Inc.
3.07%
Geode Capital Management, L.L.C.
0.92%
BlackRock Institutional Trust Company, N.A.
0.74%
Other
84.21%
持股股東
持股股東
佔比
Bleichroeder LP
6.63%
Catalytic Wealth RIA, LLC
4.42%
The Vanguard Group, Inc.
3.07%
Geode Capital Management, L.L.C.
0.92%
BlackRock Institutional Trust Company, N.A.
0.74%
Other
84.21%
股東類型
持股股東
佔比
Investment Advisor
16.85%
Investment Advisor/Hedge Fund
2.06%
Research Firm
0.54%
Individual Investor
0.35%
Hedge Fund
0.07%
Pension Fund
0.05%
Venture Capital
0.04%
Other
80.04%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
178
14.92M
19.80%
-2.21M
2025Q1
184
11.80M
15.77%
-6.74M
2024Q4
187
12.14M
19.16%
-6.53M
2024Q3
186
14.27M
23.69%
-3.80M
2024Q2
196
14.21M
29.21%
-5.75M
2024Q1
221
17.52M
36.59%
-3.12M
2023Q4
227
16.02M
35.92%
-2.73M
2023Q3
232
16.26M
36.70%
-4.68M
2023Q2
232
16.06M
37.54%
-1.73M
2023Q1
238
14.06M
33.55%
-4.01M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Bleichroeder LP
5.00M
6.63%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.32M
3.07%
+259.69K
+12.63%
Mar 31, 2025
Geode Capital Management, L.L.C.
693.89K
0.92%
+62.61K
+9.92%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
559.80K
0.74%
-4.98K
-0.88%
Mar 31, 2025
Robertson Stephens Wealth Management, LLC
478.50K
0.64%
--
--
Mar 31, 2025
Sigma Planning Corporation
326.26K
0.43%
-120.92K
-27.04%
Mar 31, 2025
BofA Global Research (US)
324.35K
0.43%
+36.00
+0.01%
Mar 31, 2025
Advisory Research, Inc.
257.23K
0.34%
--
--
Mar 31, 2025
1919 Investment Counsel, LLC
196.56K
0.26%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Avantis US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Dimensional US Core Equity 1 ETF
0%
查看更多
Avantis US Small Cap Equity ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
iShares Micro-Cap ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
Global X Russell 2000 Covered Call ETF
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
